US89157D1054 - Common Stock
TOURMALINE BIO INC
NASDAQ:TRML (5/9/2024, 3:15:20 PM)
After market: 15.77 0 (0%)15.77
+0.22 (+1.41%)
Tourmaline Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 129 full-time employees. The company went IPO on 2021-05-07. Tourmaline Bio, Inc., formerly Talaris Therapeutics, Inc., is a late-stage clinical biotechnology company. The firm is engaged in developing transformative medicines that improve the lives of patients with life-altering immune diseases. The Company’s lead program, TOUR006, is an anti-interleukin-6 (IL-6) antibody that exhibits differentiated properties, including high binding affinity to IL-6 and a naturally long half-life. TOUR006 selectively binds to IL-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. The firm focuses on developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. TED is a debilitating autoimmune disorder. ASCVD is a group of disorders caused by plaque buildup and rupture in the artery walls and includes myocardial infarctions (heart attacks) and strokes.
TOURMALINE BIO INC
27 West 24th Street, Suite 702
New York City NEW YORK
P: 15023989250.0
Employees: 129
Website: https://www.tourmalinebio.com/
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Tourmaline Bio just reported results for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tourmaline Bio (NASDAQ:TRML) just reported results for the fourth quarter of 20...
Here you can normally see the latest stock twits on TRML, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: